ClinicalTrials.gg
CompletedNCT05053139Updated Dec 8, 2025

A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors

A Phase 3 interventional study of NNC0365-3769 (Mim8) in Haemophilia A and Haemophilia A With Inhibitors, sponsored by Novo Nordisk A/S. Completed at 163 sites in 34 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2024, 2 years 8 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Mar 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
281
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 92 studies in Hemophilia A by Novo Nordisk A/S — 8 open to participants now, 12 under way, 5 of them phase 3. Hemophilia A · Novo Nordisk A/S.

Enrollment
2nd of 59
281 · median 38
Started
2021
with 4 others
Phase 3
21 of 92
1 open now
Registered
75th of 92
by date

Among the 92 studies in Hemophilia A by Novo Nordisk A/S, this one is the 2nd largest by enrollment of the 59 interventional ones that give a count, is one of 5 that started in 2021, is one of 21 in phase 3, and was the 75th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

8 of the 92 studies in Hemophilia A by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Hemophilia A by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study is investigating how Mim8 works compared to other medicines in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used for prevention of bleeding episodes. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII).

When and how often participants will receive Mim8 is dependent on their previous treatment - but is otherwise decided by chance. Mim8 will be injected into a skinfold on the stomach with a thin needle either once a week or once a month.

The study will last 54-124 weeks (12-29 months) depending on how long participants will be followed in run-in before they start treatment and if they continue in the follow period or transfer to an open label extension study. Participants will have 12-17 clinic visits.

03

Conditions studied

  • Haemophilia A
  • Haemophilia A With Inhibitors

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
  2. Male or female participants with diagnosis of congenital haemophilia A of any severity based on medical records.
  3. Participant has been prescribed treatment with factor VIII concentrates or bypassing agent in the last 26 weeks prior to screening.
  4. Age above or equal to 12 years at the time of signing informed consent.
  5. Body weight greater than or equal to 30 kg.
  6. Applicable to participants treated with on-demand/no prophylaxis prior to enrolment: ≥5 bleeds in the last 26 weeks prior to screening visit, for which factor VIII concentrates or bypassing agent has been prescribed.
  7. Applicable to participants with FVIII activity ≥1% who are on prophylactic treatment: ≥1 bleed in the last 26 weeks prior to screening visit, for which factor VIII concentrates or bypassing agent has been prescribed.
  8. Willingness and ability to comply with scheduled visits and study procedures, including the completion of diary and patient-reported outcomes questionnaires.

Exclusion criteria

Exclusion Criteria:

  1. Previous participation in this study. Participation is defined as signed .
  2. Participation (i.e., signed informed consent) in any interventional clinical study with receipt of the last dose within 6 months (or 5 half-lives of the medicinal product, whichever is shorter) before planned randomisation.
  3. Exposure to non-factor haemostatic products for bleeding prophylaxis within 6 months (or 5 half-lives of the medicinal product, whichever is shorter) before planned randomisation, for participants not included in the run-in.
  4. Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using a highly effective method. Breast feeding is allowed only during the run-in period.
  5. Any disorder, except for conditions associated with haemophilia A, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
  6. Known or suspected to trial product(s), any constituents of the product or to related products.
  7. Receipt of gene therapy at any given time point.
  8. Ongoing or planned immune tolerance induction (ITI) therapy.
  9. Major surgery planned to take place after screening.
  10. Known congenital or acquired coagulation disorders other than haemophilia A.
  11. Hepatic dysfunction defined as (AST) and/or alanine aminotransferase (ALT) above 3 times the upper limit combined with total above1.5 times the upper limit measured at screening.
  12. Renal impairment defined as estimated (eGFR) below or equal to 30 ml/min/1.73 m\^2 for serum creatinine measured at screening.
  13. Previous or current thromboembolic disease or events (with the exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing) or risk of thromboembolic disease, as evaluated by investigator.
  14. Mental incapacity, unwillingness to cooperate, or a language barrier precluding adequate understanding and cooperation.
  15. Other conditions (e.g., disease) or laboratory abnormality that may increase risk of bleeding or thrombosis as evaluated by the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
281 participants (actual)

Study arms

  • Experimental
    no PPX- no PPX - Mim8 PPXQW/QM

    Participants not receiving prophylaxis will not enter the run-in period. In arm 1, participants will be randomised to continue no prophylaxis (on-demand treatment with their Standard of Care products) or Mim8 once-weekly or once-monthly prophylaxis in agreement with investigators in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) in agreement with the investigator, either weekly or monthly Mim8 prophylaxis regimen.

    Drug: NNC0365-3769 (Mim8)

  • Experimental
    no PPX - Mim8 PPXQW - Mim8 PPXQW

    Participants not receiving prophylaxis will not enter the run-in period. In arm 2a, participants will be randomised to Mim8 once-weekly prophylaxis in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-weekly Mim8 prophylaxis regimen.

    Drug: NNC0365-3769 (Mim8)

  • Experimental
    no PPX - Mim8 PPXQM - Mim8 PPXQM

    Participants not receiving prophylaxis will not enter the run-in period. In arm 2b, participants will be randomised to Mim8 once-monthly prophylaxis in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-monthy Mim8 prophylaxis regimen.

    Drug: NNC0365-3769 (Mim8)

  • Experimental
    PPX - Mim8 PPXQW

    Participants on coagulation factor prophylaxis prior to enrolment will preferably continue the same product type and dosing frequency in the run-in period for at least 26 weeks before they can be randomised into the main part of the study. These participants will only be allowed to receive coagulation factor prophylaxis. In arm 3, participants will be randomised to once-weekly Mim8 prophylaxis regimen in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-weekly Mim8 prophylaxis regimen.

    Drug: NNC0365-3769 (Mim8)

  • Experimental
    PPX- Mim8 PPXQM

    Participants on coagulation factor prophylaxis prior to enrolment will preferably continue the same product type and dosing frequency in the run-in period for at least 26 weeks before they can be randomised into the main part of the study. These participants will only be allowed to receive coagulation factor prophylaxis. In arm 4, participants will be randomised to once-monthly Mim8 prophylaxis regimen in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-monthly Mim8 prophylaxis regimen.

    Drug: NNC0365-3769 (Mim8)

Interventions

  • Mim8 will be injected into a skinfold on the stomach with a thin needle either once a week or once a month.

06

What researchers measure

Primary outcomes

  1. Number of treated bleeds

    Count

    Time frame: No prophylaxis treatment (Arms 1, 2a and 2b): From randomisation (week 0) to end of main (week 26)

  2. Number of treated bleeds

    Count

    Time frame: Prophylaxis treatment (Arms 3 and 4): From initiation of run-in (26-52 weeks prior to week 0) to week 0 and from randomisation (week 0) to end of main (week 26)

Secondary outcomes

  1. Number of injection site reactions

    Count

    Time frame: All participants receiving Mim8 (Arms 2a, 2b, 3 and 4): From randomisation (week 0) to end of main (week 26)

  2. Occurrence of anti-Mim8 antibodies

    Count

    Time frame: All participants receiving Mim8 (Arms 2a, 2b, 3 and 4): From randomisation (week 0) to end of extension (week 52)

  3. Number of treated spontaneous bleeds

    Count

    Time frame: No prophylaxis treatment (Arms 1, 2a and 2b): From randomisation (week 0) to end of main (Week 26) Prophylaxis treatment (Arms 3 and 4): From initiation of run-in (26-52 weeks prior to week 0) to week 0 and from week 0 to end of main (week 26)

  4. Number of treated joint bleeds

    Count

    Time frame: No prophylaxis treatment (Arms 1, 2a and 2b): From randomisation (week 0) to end of main (Week 26) Prophylaxis treatment (Arms 3 and 4): From initiation of run-in (26-52 weeks prior to week 0) to week 0 and from week 0 to end of main (week 26)

  5. Number of treated traumatic bleeds

    Count

    Time frame: No prophylaxis treatment (Arms 1, 2a and 2b): From randomisation (week 0) to end of main (Week 26) Prophylaxis treatment (Arms 3 and 4): From initiation of run-in (26-52 weeks prior to week 0) to week 0 and from week 0 to end of main (week 26)

  6. Number of target joint bleeds

    Count

    Time frame: No prophylaxis treatment (Arms 1, 2a and 2b): From randomisation (week 0) to end of main (Week 26) Prophylaxis treatment (Arms 3 and 4): From initiation of run-in (26-52 weeks prior to week 0) to week 0 and from week 0 to end of main (week 26)

  7. Consumption of factor product per bleed treatment (number of injections)

    Count

    Time frame: No prophylaxis treatment (Arms 1, 2a and 2b): From randomisation (week 0) to end of main (Week 26) Prophylaxis treatment (Arms 3 and 4): From initiation of run-in (26-52 weeks prior to week 0) to week 0 and from week 0 to end of main (week 26)

  8. Change in physical function domain of PEDS-QL (pediatric quality of life inventory)

    Score points Minimum score per question (best) = 0 Maximum score per question (worst) = 4 Total score for 13 questions: 0 (best) to 92 (worst)

    Time frame: All participants (Arms 1, 2a, 2b, 3 and 4): From randomisation (week 0) to the end of the main part (week 26)

  9. Change in patient's treatment burden using the Hemo-TEM (haemophilia treatment experience measure)

    Score points Ranges from 0 (best) - 4 (worst) representing answers ranging: 'Not at all difficult' - 'Extremely difficult' 'Never' - 'always' 'Not at all bothered' - 'Extremely bothered' 'Not at all interfering' - 'Extremely interfering' 'Not at all burdened' - 'Extremely burdened'

    Time frame: All participants (Arms 1, 2a, 2b, 3 and 4): From randomisation (week 0) to the end of the main part (week 26)

  10. Change in patient's joint pain score using Joint Pain Rating Scale

    Score points ranges from 0 = 'not at all' (best) to 4 = 'extremely' (worst)

    Time frame: All participants (Arms 1, 2a, 2b, 3 and 4): From randomisation (week 0) to the end of the main part (week 26)

07

Study locations

163 sites
  • Arizona H&T Phoenix Child Hosp
    Phoenix, Arizona 85016-7710, United States
  • Hemophilia Treatment Center
    Los Angeles, California 90007, United States
  • Children's Hospital Los Angeles - Endocrinology
    Los Angeles, California 90027, United States
  • Univ of Colorado Sch of Med
    Aurora, Colorado 80045, United States
  • Univ of Miami/SCCC
    Miami, Florida 33136, United States
  • Arnold Palmer Hospital for Children
    Orlando, Florida 32806, United States
  • St Joseph's Hospital Foundation
    Tampa, Florida 33607, United States
  • Children HC Atlanta-Adv Pediat
    Atlanta, Georgia 30329, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Memorial Health Univ Med Ctr
    Savannah, Georgia 31404, United States
  • Rush University Med. Cntr
    Chicago, Illinois 60612, United States
  • Indiana Hemophilia-Thromb Ctr
    Indianapolis, Indiana 46260, United States
  • University of Iowa_Iowa City
    Iowa City, Iowa 52242, United States
  • University Of Iowa
    Iowa City, Iowa 52242, United States
  • Children's Hosp-New Orleans
    New Orleans, Louisiana 70118-5720, United States
  • University Of Michigan
    Ann Arbor, Michigan 48109, United States
  • Michigan State University
    East Lansing, Michigan 48823, United States
  • Washington University School of Medicine_St. Louis
    St Louis, Missouri 63110, United States
  • Univ of NE Med Center_Omaha
    Omaha, Nebraska 68105, United States
  • Cure 4 the Kids Foundation
    Las Vegas, Nevada 89135, United States
  • Torrence Hemby Ped Hem/Onc Ctr
    Charlotte, North Carolina 28203, United States
  • St. Jude Clinic Novant Health
    Charlotte, North Carolina 28204, United States
  • Cincinnati Child's Hsp Med Ctr
    Cincinnati, Ohio 45229, United States
  • Univ Hosp Cleveland Med Ctr
    Cleveland, Ohio 44106, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Dayton Children Hemostati Ctr
    Dayton, Ohio 45404, United States
  • Penn State MS Hershey Med Ctr
    Hershey, Pennsylvania 17033-2360, United States
  • St Christopher Hosp for Child
    Philadelphia, Pennsylvania 19134, United States
  • Balad Hlth Sys-Welmont CardCVA
    Kingsport, Tennessee 37660, United States
  • Vanderbilt Hemostasis Thrombosis Clinic
    Nashville, Tennessee 37232-9830, United States
  • Children's Medical Center_Dallas
    Dallas, Texas 75235, United States
  • Univ TX Hlth Sci Ctr Houston
    Houston, Texas 77030, United States
  • Providence Sacred Heart Medical Center & Children's Hospital
    Spokane, Washington 99204, United States
  • Children's Hospital of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Universitätsklinik für Innere Medizin V
    Innsbruck, 6020, Austria
  • AKH - Klin. Abt. f. Haematologie u. Haemostaseologie
    Vienna, 1090, Austria
  • Cliniques universitaires Saint-Luc - Service Hématologie
    Brussels, 1200, Belgium
  • UZ Antwerpen - UZA - Kinderhemato-Oncologie
    Edegem, 2650, Belgium
  • UZ Leuven - Kindergeneeskunde
    Leuven, 3000, Belgium
  • University of Manitoba
    Winnipeg, Manitoba R3T 2N2, Canada
  • St. John Regional Hospital
    Saint John, New Brunswick E2L 4L4, Canada
  • Eastern Health Authority
    St. John's, Newfoundland and Labrador A1B 3V6, Canada
  • McMaster University Medical Center
    Hamilton, Ontario L8N 3Z5, Canada
  • McMaster University
    Hamilton, Ontario L8N 3Z5, Canada
  • London Health Sciences Center Ontario
    London, Ontario N6A 5W9, Canada
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • Hopital Maisonneuve Rosemont
    Montreal, Quebec HIT 2M4, Canada
  • Royal University Hospital
    Saskatoon, Saskatchewan S7N 0W8, Canada
  • Beijing Children's Hospital, Capital Medical University
    Beijing, Beijing Municipality 100045, China
  • Haemotology, Nanfang Hospital, Southern Medical University
    Guangzhou, Guangdong 510515, China
  • Nanfang Hospital, Southern Medical University-Haematology
    Guangzhou, Guangdong 510515, China
  • Tongji Hospital, Tongji Medical College of HUST-Hematology
    Wuhan, Hubei 430030, China
  • Tongji Hospital, Tongji Medical College of HUST
    Wuhan, Hubei 430030, China
  • Xiangya Hospital Central-South University
    Changsha, Hunan 410008, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
  • Jinan Central Hospital
    Ji'Nan, Shandong 250000, China
  • Jinan Central Hospital
    Jinan, Shandong 250000, China
  • Chengdu Women's and Children's Central Hospital
    Chengdu, Sichuan 610074, China
  • Institute of Hematology and Blood Diseases Hospital, Tianjin-Hematology
    Tianjin, Tianjin Municipality 300020, China
  • The Second Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650101, China
  • Children's Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310052, China
  • The Children's Hospital, Zhejiang University school of medicine
    Hangzhou, Zhejiang 310052, China
  • Ustav Hematologie a krevni tranfuze
    Prague, 128 20, Czechia
  • Rigshospitalet - Department of Haematology, 2081
    København Ø, 2100, Denmark
  • Centre Hospitalier Universitaire de Bordeaux-Hopital Pellegrin
    Bordeaux, 33076, France
  • Hospices Civils de Lyon- Hopital Louis Pradel-1
    Bron, 69500, France
  • Hôpital Cardiologique Louis Pradel
    Bron, 69500, France
  • Ap-Hp-Hopital de Bicetre-1
    Le Kremlin-Bicêtre, 94275, France
  • Centre Hospitalier Universitaire de Lille-Institut Coeur Poumon
    Lille, 59037, France
  • Centre Hospitalier Universitaire de Nantes-Hopital Hotel-Dieu
    Nantes, Nantes, France
  • Ap-Hp-Hopital Necker-1
    Paris, 75015, France
  • Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou
    Rennes, 35033, France
  • Vivantes Netzwerk für Gesundheit GmbH - Vivantes Klinikum im Friedrichshain
    Berlin, 10249, Germany
  • Universitätsklinikum Bonn - Institut für Experimentelle Hämatologie
    Bonn, 53127, Germany
  • HZRM Haemophilie-Zentrum Rhein Main GmbH
    Frankfurt am Main, 60596, Germany
  • Nirmal Hospital Pvt. Ltd.
    Surat, Gujarat 395002, India
  • Seth GS Medical College & KEM Hospital
    Mumbai, Maharashtra 400012, India
  • Christian medical college
    Ludhiana, Punjab 141008, India
  • CMCV
    Ranipet, Tamil Nadu 632517, India
  • Post Graduate Institute of Child Health
    Noida, Uttar Pradesh 201303, India
  • St James's CRF
    Dublin, Leinster D08 A978, Ireland
  • CHI Crumlin Haematology
    Dublin, D12 N512, Ireland
  • Sheba MC - The Israeli National Hemophilia Center
    Tel Litwinsky, 52621, Israel
  • Dipartimento di Ematologia Univ. Firenze
    Florence, 50134, Italy
  • IRCCS Humanitas Research Hospital - Centro Trombosi e Malattie Emorragiche
    Milan, 20089, Italy
  • Nagoya University Hospital_Blood Transfusion
    Aichi, 466-8560, Japan
  • Hospital of the University of Occupational And Environmental Health Japan, Pediatrics
    Kitakyusyu-shi, Fukuoka, 807 8555, Japan
  • Nanbu Medical Center & Children's Medical Center
    Okinawa, 901-1193, Japan
  • Saitama Children's Med Centre_Hematology-Oncology
    Saitama, 330-8777, Japan
  • Shizuoka Children's Hospital, Hematology-Oncology
    Shizuoka, 420-8660, Japan
  • Jichi Medical University Hospital_Hematology
    Tochigi, 329-0498, Japan
  • Jichi Medical University Hospital_Pediatrics
    Tochigi, 329-0498, Japan
  • National Center for Child Health and Development_Hematology
    Tokyo, 157-8535, Japan
  • Tokyo Medical Univ. Hospital_Laboratory Medicine
    Tokyo, 160-0023, Japan
  • Ogikubo Hospital_Pediatries & Blood
    Tokyo, 167-0035, Japan
  • Stradini Clinic of Oncology
    Riga, 1002, Latvia
  • Children University Clinical Hospital
    Riga, 1004, Latvia
  • Hospital of LUHS "Kauno Klinikos"
    Kaunas, LT-50161, Lithuania
  • Children Oncohaematology department Children's Hospital,
    Vilnius, 08406, Lithuania
  • Vilnius University hospital Santaros klinikos
    Vilnius, LT-08661, Lithuania

Showing the first 100 of 163 sites across 34 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Mancuso ME, Chan AKC, Shanmukhaiah C, Lyu CJ, Zdziarska J, Mahlangu J, van Vulpen LFD, Chowdary P, Yang R, Lentz SR, Matsushita T, Clausen WHO, Rakhmatullin I, Oldenburg J; FRONTIER2 Investigators. Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors. N Engl J Med. 2026 Apr 30;394(17):1696-1709. doi: 10.1056/NEJMoa2517384. PubMed 42054679 ↗
  • Ong Clausen WH, Latendorf T, Stehr R, Ezban M, Lund J. Comparative ex vivo analysis of Mim8 in thrombin generation assays triggered by activated factor XI or tissue factor. Res Pract Thromb Haemost. 2025 Oct 10;9(7):103209. doi: 10.1016/j.rpth.2025.103209. eCollection 2025 Oct. PubMed 41257207 ↗

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Mar 2024, 27 months.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 27 months is below that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2021
First posted
Sep 22, 2021
StartActual
Dec 2, 2021
Primary completionActual
Mar 11, 2024
CompletionActual
Dec 17, 2024
Results delay requested
Mar 10, 2025
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05053139
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 22, 2021
Start date
Dec 2, 2021
Primary completion
Mar 11, 2024
Completion
Dec 17, 2024
Last update
Dec 8, 2025

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denecimig

Start the discussion